Business Standard

Intas launches chemotherapy drug at affordable price

It is estimated that every year over 700,000 patients die due to various types of cancer in India

This microbot can capture cells like a tiny Pac-Man, may help probe cancer
Premium

An electron micrograph of a prostatic cancer cell. Photo: Reuters

BS Reporter Ahmedabad
Ahmedabad-based Intas Pharmaceuticals has launched the cancer drug Bevacizumab at prices 60 per cent less than the currently available options. 

On Wednesday, the company announced that its Bevacizumab therapy would cost Rs 39,995 for the dose strength of 400 mg variant, which makes it 60 per cent less than the currently available options. 

It would bring relief to a large number of cancer patients in India for whom the drug was out of reach until now. The drug was available in India since 2004. However, the cost of therapy was high. 

It is estimated that every year over 700,000 patients die due to

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in